Ordinary Shares International Reporting
Verified Company Profile 5/01/2017
Contact Info
  • c.o DiaMedica USA Inc.
  • 2 Carlson Pkwy, Ste 165
  • Minneapolis, MN 55447

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Jun 30, 2017 Interim Financial Report
CIK 0001401040
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Manitoba, Canada
Year of Inc. 2000
Employees Not Available
Company Officers/Contacts
Rick John Pauls President, CEO
Paul Papi VP, Bus. Dev. & Corp. Rel.
David Gurvey VP, Fin.
Todd Verdoorn CSO
Donna Husemoller Corporate Controller
Company Directors
Richard Dal Pilnik Chairman, Independent Director, Compensation Committee Member, Nominating Committee Member
Michael Giuffre Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
James Parsons Audit Committee Member, Compensation Committee Member, Nominating Committee Member
Zhenyu "Jerry" Xiao Independent Director
Service Providers
Accounting/Auditing Firm
333 Bay Street Suite 4600
Bay Adelaide Centre
Toronto, ONT, M5H 2S5
Securities Counsel
Pushor Mitchell LLP
301-1665 Ellis Street
Kelowna, BC, V1Y 2B3
Investor Relations Firm

Not Available
Company History
  • Formerly=Diamedica, Inc. until 12-2016
DMCAF Security Details
Share Structure
Market Value1 $35,920,418 a/o Oct 17, 2017
Authorized Shares Unlimited a/o Jun 29, 2016
Outstanding Shares 121,107,275 a/o Apr 30, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
Transfer Agent(s)
Shareholders of Record Not Available
Non US Stock Exchange Listing
DMA - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 700 (16.67%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security